ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements
Pharmaids Pharmaceuticals filed legal complaints against Anugraha Chemicals for dishonoured cheques totalling ₹2.63 Crore in outstanding dues from a disinvestment agreement.
Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.
KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.
Pharmaids Pharmaceuticals Limited has issued the notice for its 37th Annual General Meeting, scheduled for September 11, 2026, along with the Annual Report for 2025-26.
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹4.1 Cr (-38.8% YoY) and net profit of ₹1.9 Cr (-64.2% YoY) for Q1 FY27.
Pharmaids Pharmaceuticals scheduled a board meeting for August 12, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Pharmaids Pharmaceuticals appointed M/s. V Mahendra & Associates as internal auditors. The appointment is for the financial year 2026-27.
Dr. Jagadeesh M N has resigned as Vice President - Discovery Services. The resignation is effective from June 25, 2026.
Pharmaids Pharmaceuticals issued a Rs.0.55 Crore corporate guarantee to State Bank of India for its subsidiary Adita Bio Sys. This creates a contingent liability for the company.
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹7.2 Cr (+50.0% YoY) and a net loss of ₹1.1 Cr for Q4 FY26.
Pharmaids Pharmaceuticals reported audited FY26 results and approved a ₹0.75 Crore corporate guarantee for its subsidiary. Performance details and subsidiary support reflect ongoing operational strategy.
Pharmaids Pharmaceuticals scheduled a board meeting for May 29, 2026, to approve audited financial results. The trading window remains closed for designated persons until June 1.
Pharmaids Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. This confirms the company's adherence to SEBI's regulatory disclosure standards.
Pharmaids Pharmaceuticals Ltd submitted a compliance certificate for the quarter ended March 31, 2026, regarding the dematerialization of shares. The Registrar and Share Transfer Agent confirmed that share certificates received for dematerialization were processed and canceled within the prescribed 15-day timeline.